June 28th, 2023

Biopharmaceutical leader Gilead Sciences, Inc. (Nasdaq: GILD) has disclosed its acquisition of 2,930,870 shares of AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, in a regulatory filing FORM 4 with the SEC. The shares were a. Read more

June 28th, 2023

Shares of Micron Technology, Inc. (Nasdaq: MU) surged in after-hours trading following the release of its better-than-expected financial results. In the third quarter of fiscal 2023, Micron reported a loss of $1.43 per share and revenue of $3.752 . Read more

June 28th, 2023

General Mills, Inc. (NYSE: GIS) released its fourth-quarter fiscal 2023 earnings report, surpassing the consensus estimates for earnings per share (EPS).  The company reported an EPS of $1.12, exceeding the consensus of $1.07. However, its sa. Read more

June 28th, 2023

Pfizer Inc. (NYSE: PFE) and  OPKO Health Inc. (Nasdaq: OPK) said that the  U.S. Food and Drug Administration  (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly treatment for pediatric patients with growth hormone deficiency (G. Read more

June 28th, 2023

Bidenomics, the economic vision of President Biden, has proven to be successful in growing the economy from the middle out and bottom up, rather than relying on a top-down approach. The strategy was implemented to address longstanding challenges in t. Read more

June 28th, 2023

Theriva Biologics, Inc. (NYSE American: TOVX) made a significant announcement as the U.S. FDA granted orphan drug designation to VCN-01, the company's innovative oncolytic adenovirus, for treating pancreatic cancer. VCN-01 is designed to selective. Read more

June 27th, 2023

Meta Platforms, Inc. (Nasdaq: META), a prominent social media and technology company, was maintained with a Buy rating by Citigroup, who raised the price target from $315 to $360.  Despite $META closing at $287.05 on Tuesday, the revised pric. Read more

June 27th, 2023

AeroVironment, Inc. (Nasdaq: AVAV) reported fourth-quarter fiscal 2023 adjusted EPS of $0.99, slightly below the consensus estimate of $1.01. Looking ahead to the full-year fiscal 2024, the company anticipates revenue ranging between $630 million . Read more

June 27th, 2023

The U.S. Department of State, the U.S. Department of the Treasury, the U.S. Department of Commerce, the U.S. Department of Homeland Security, the U.S. Department of Labor, and the United States Agency for International Development issued a business r. Read more

June 27th, 2023

Shares of Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) tumbled more than 8% during intraday trading in response to the company receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). The CRL was issued for th. Read more